Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price | Target price ▼ | Potential |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 47 | 1 | 9 | 0 | €1,072.0 | €1,091.9 | 1.858% |
| Eli Lilly Corp. | 68 | 0 | 9 | 0 | €867.80 | €883.50 | 1.809% |
| Vertex Pharmaceuticals Inc. | 58 | 2 | 7 | 0 | €448.50 | €450.36 | 0.416% |
| Medpace Holdings Inc | 16 | 0 | 0 | 0 | €321.70 | €418.12 | 29.973% |
| United Therapeutics | 27 | 1 | 5 | 1 | €329.00 | €341.51 | 3.802% |
| Madrigal Pharmaceuticals inc. | 3 | 0 | 0 | 0 | €223.80 | €315.00 | 40.751% |
| Amgen Inc. | 28 | 0 | 3 | 0 | €301.95 | €304.82 | 0.950% |
| Biogen Inc. | 51 | 2 | 5 | 1 | €185.20 | €284.87 | 53.817% |
| Alnylam Pharmace. | 46 | 1 | 8 | 1 | €237.70 | €271.50 | 14.221% |
| Charles River Labs Intl | 13 | 0 | 2 | 0 | €178.90 | €247.61 | 38.406% |
| Zoetis Inc. A | 25 | 1 | 4 | 0 | €166.00 | €198.11 | 19.344% |
| Johnson & Johnson | 40 | 1 | 2 | 0 | €150.02 | €187.62 | 25.060% |
| Krystal Biotech | 20 | 0 | 4 | 0 | €176.40 | €185.58 | 5.204% |
| AbbVie Inc. | 34 | 0 | 3 | 0 | €177.58 | €181.45 | 2.178% |
| Repligen Corp. | 15 | 0 | 3 | 0 | €130.50 | €178.01 | 36.408% |
| Neurocrine Bioscience | 45 | 0 | 10 | 0 | €115.00 | €149.74 | 30.205% |
| Sarepta Therapeutics | 1 | 0 | 0 | 0 | €125.00 | €130.00 | 4.000% |
| Merck & Co. Inc. | 33 | 1 | 5 | 0 | €107.20 | €125.91 | 17.451% |
| Abbott Laboratories | 20 | 0 | 2 | 0 | €102.48 | €116.25 | 13.434% |
| BioMarin Pharmaceutical Inc. | 23 | 0 | 7 | 0 | €82.52 | €102.48 | 24.183% |
| Gilead Sciences Inc | 12 | 1 | 1 | 0 | €71.46 | €84.81 | 18.685% |
| Ultragenyx Pharmaceutical Inc. | 25 | 1 | 4 | 0 | €51.00 | €84.74 | 66.165% |
| Intra-Cellular Therapies Inc. | 31 | 0 | 3 | 0 | €66.50 | €84.73 | 27.411% |
| Cytokinetics Inc. | 30 | 1 | 1 | 0 | €52.00 | €84.53 | 62.557% |
| Prothena Corp. plc | 13 | 0 | 2 | 0 | €19.10 | €78.70 | 312.045% |